NCT01638546 2025-10-29
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Columbia University
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center